European Union: Panel Says European Drug Agency Should Approve Combination HIV Drug Atripla
October 22, 2007
Gilead Sciences Inc., Bristol-Myers Squibb Co., and Merck & Co. said Thursday the EU's Committee for Medicinal Products for Human Use, part of the European Medicines Agency, has recommended its once-a-day HIV drug Atripla be approved for sale. The panel said Atripla should be approved for adults who have not been treated with other HIV therapies. Atripla combines efavirenz, emtricitabine, and tenofovir. An agency ruling is expected by the end of 2007.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.